about
Mechanism and significance of cell type-dependent neutralization of flavivirusesThe dengue vaccine pipeline: Implications for the future of dengue controlDengue Antibody and Zika: Friend or Foe?Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteersMaturation of West Nile Virus Modulates Sensitivity to Antibody-Mediated NeutralizationPhenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue feverPhase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicityPhase 1 Trial of the Dengue Virus Type 4 Vaccine Candidate rDEN4 30-4995 in Healthy Adult VolunteersMapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to DENV4 Infection and VaccinationPatterns of cellular immunity associated with experimental infection with rDEN2Δ30 (Tonga/74) supports its suitability as a human DENV challenge strainHuman CD4+ T cell responses to an attenuated tetravalent dengue vaccine parallel those induced by natural infection, in magnitude, HLA restriction and antigen specificityPhase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adultsAntibody responses to Zika virus infections in flavivirus-endemic environmentsIn a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccinationPhase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malariaA dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virusA single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial.The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals.Report of an NIAID workshop on dengue animal models.Comparing the understanding of subjects receiving a candidate malaria vaccine in the United States and MaliViscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data.Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines.Primary vaccination with low dose live dengue 1 virus generates a proinflammatory, multifunctional T cell response in humans.Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria.Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic.The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes.The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccineNext-generation dengue vaccines: novel strategies currently under development.Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive AntibodiesViral kinetics of primary dengue virus infection in non-human primates: a systematic review and individual pooled analysisTargeted mutagenesis as a rational approach to dengue virus vaccine development.Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults.Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive AdultsActive Surveillance for Adverse Events After a Mass Vaccination Campaign With a Group A Meningococcal Conjugate Vaccine (PsA-TT) in MaliDevelopment of a live attenuated dengue virus vaccine using reverse genetics.Systemic pharmacokinetics of rifaximin in volunteers with shigellosis.A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trialEmergence potential of sylvatic dengue virus type 4 in the urban transmission cycle is restrained by vaccination and homotypic immunity.
P50
Q23032973-6C729E80-F9BD-4168-BAFD-B3F52A257391Q26314683-7876A1CF-5157-48F6-9D1D-B08A144745ADQ26810984-E489FF36-5440-46F1-B6E8-1E2ACC9959F8Q27485433-DA33017A-C49E-4A8D-AA8B-48C3E7C8A8D8Q27485890-29DE21A6-6F33-4D40-8817-0A7CE9D75954Q27486912-3B8D8603-0EC3-4741-86D0-F7C766EC1257Q27487377-007729A2-CAB6-457D-B426-FA8CB2202B25Q27490989-B51A6377-F5BE-4E0C-B6D3-F258D29B0649Q28114614-6A10DEF7-1E38-405C-8697-1D81DFDC9EF5Q28729784-32DA3261-80CA-44E6-9E0D-9AADFBC77C7DQ28733418-FF2F8D8F-96CA-4F11-9B3A-EE120769BB91Q28749215-868E85E2-973E-45A5-9764-C756B0FD0AFDQ28827957-6A63791B-B445-4F8B-BCF8-5A39B905A0CBQ30250977-AC32EB70-8CEE-4DBB-AD5A-7D237CABB68DQ33350210-589D6608-34A8-4B69-B067-367A9B809F42Q33788306-EEFE1E60-9EE6-4519-B78F-ADB820CD4F9CQ33954392-BAE69471-076A-478E-914F-D9F93D2D32A6Q33988937-BBEB160B-1B76-447D-9D0D-A500C1BB09E2Q34021580-603292FE-A1BD-4483-92EF-588AE8AA6FCAQ34058747-4A5F29EE-D2C1-4EB5-B9CD-C0041591596BQ34160143-1C757C68-8FCC-4F35-8491-5A62F8DF2178Q34258885-FC1E1F81-B29C-43E4-9301-4056D347DB08Q34285502-71D8723B-D34B-480D-AA68-B71FF6D6ED57Q34345965-D8591D72-7DD5-413A-85EA-0108F00CC060Q34441098-221A340D-AE7E-43EF-AA5D-3B258A2C152AQ34763787-ABCA9EFE-DF05-4746-845D-698CFFD32833Q34992520-E96AF7E0-E340-4641-9F59-E2002AD2A14DQ35069160-A70C9774-C45F-4EB1-BE1F-884A6F604A1EQ35206695-09356098-8D61-4680-A832-D1D2FAE7E5F9Q35491639-31CFA993-19A4-4DD4-ABC9-E9B66657D410Q35758626-1EA61181-409B-4995-9824-8976C3516647Q36082908-546A2369-0ED3-4DF6-AF66-A11AE5277CF1Q36118259-EA5ACD73-6065-4DA2-9BB9-393292F06934Q36165265-494BCE79-E0A6-4B2F-852D-4AA14A48D282Q36181531-EC8EFCF5-2ABF-4BAA-B0A0-268D6F0D5978Q36265001-A7093989-6E58-4DC0-9343-4302F6A74A8DQ36428460-0686864D-767A-4625-864D-74B04992A153Q36482910-39377CD4-89D1-4B47-BBBB-A2FE7EE08AA7Q36607295-EBCF9809-B35C-4A0C-BC65-5D9838E12059Q36756643-DA2404DF-4900-4034-A8D6-AD2761E62FEB
P50
description
researcher
@en
name
Anna Durbin
@en
type
label
Anna Durbin
@en
prefLabel
Anna Durbin
@en
P31
P496
0000-0002-6652-2851